The event gathered top local and international experts in the field of Cardiovascular-Renal-Metabolic, along with over 800 healthcare professionals attending both in person and virtually. Discussions centered around the latest treatment trends, highlighting the importance of early intervention and comprehensive disease management for Cardiovascular-Renal-Metabolic patients.
The symposium gathered top experts in the field of Cardiovascular-Renal-Metabolicfrom both Vietnam and abroad, with the participation of over 800 healthcare professionals joining onsite and online.
The symposium served not only as a platform for in-depth scientific exchange but also marked a significant step forward in the journey of treatment innovation – both in Vietnam and globally. With the latest clinical data and proven therapeutic outcomes, the event opened new pathways for improving Cardiovascular-Renal-Metabolic health outcomes and enhancing quality of life for millions of patients worldwide.
At the "A Decade of Easy Choice for Protection" symposium, experts strongly emphasized the need for early intervention and multidisciplinary collaboration to effectively manage Cardiovascular-Renal-Metabolic diseases.
In Vietnam, approximately 7 million people are currently living with type 2 diabetes. Research estimates that with timely intervention and early treatment, more than 21,682 lives with type 2 diabetes could be saved annually, and over 17,000 cardiovascular-related deaths could be prevented. Additionally, early disease management could also save an estimated 588 billion VND per year by reducing the need for dialysis and the treatment of related complications.
Professor Nguyen Lan Viet, Standing Vice President of the Vietnam National Heart Association, delivered a keynote address at the symposium
Professor Nguyen Lan Viet, Standing Vice President of the Vietnam National Heart Association, shared: "Cardiovascular, renal, and metabolic diseases are deeply interconnected and often coexist, creating a cycle that increases health risks and accelerates disease progression. This close association underscores the urgent need for early intervention through timely screening, diagnosis, and treatment to better manage these conditions and improve outcomes for patients at risk".
Professor Javed Butler, President of Baylor Scott and White Research Institute (USA), added: "Proactive screening, especially among high-risk populations, is one of the most effective ways to prevent severe complications. Early detection and timely treatment not only extend patients’ lives but also significantly improve their quality of life - easing both physical suffering and emotional burdens for patients and their families".
Mr. Oliver Koehncke, General Manager of Boehringer Ingelheim Vietnam, delivered his remarks at the symposium
According to Mr. Oliver Koehncke, General Manager of Boehringer Ingelheim Vietnam, Empagliflozin is not just a medical innovation – it is a testament to Boehringer Ingelheim’s commitment to patients, healthcare professionals, and healthcare systems worldwide. "The 10-year journey of advancing Cardiovascular-Renal-Metabolic protection with Empagliflozin marks a meaningful milestone, contributing to a more comprehensive treatment landscape for Cardiovascular-Renal-Metabolic conditions. The research and development of Empagliflozin clearly demonstrate Boehringer Ingelheim’s long-standing legacy of continuous innovation aimed at driving positive change and helping to save millions of lives. Looking ahead, we remain committed to advancing research and developing breakthrough solutions in the Cardiovascular-Renal-Metabolic field - continuing our mission to transform lives for generations. Because to us, every heartbeat matters" – Mr. Oliver Koehncke added.
